NIBEC is established as a spin-off venture from Seoul National University, South Korea at 2004 and listed in Korean Stock Market (KOSDAQ) at 2011. The company's main technology is based on target-oriented peptide therapeutic discovery (TOPscovery) platform for drug discovery, delivery, and development. The company’s focus of therapeutic area includes inflammatory bowel disease (IBD), pulmonary fibrosis and oncology with well-defined mode of action. The peptide assets for both IBD and pulmonary fibrosis treatment have been in global phase I study, now in preparation of phase II study. In addition to the therapeutic peptide asset, NIBEC has drug delivery platforms; 1) target tissue/cell penetrating peptide carrier specialized for the delivery to the brain (BBB shuttle) or cancer and 2) oral peptide/protein delivery formulation. In addition to the drug development, the company already has entered the regenerative market using tissue engineering biomaterials.
Ticker:
138610
Exchange:
KOSDOQ
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Seoul
Company HQ Country:
Korea, Republic of
Year Founded:
2004
Main Therapeutic Focus:
Gastrointestinal
Lead Product in Development:
Peptide therapeutics for the treatment of Inflammatory Bowel Disease (NIPEP-IBD)
Peptide therapeutics for the treatment of Pulmonary Fibrosis (NIPEP-PF)
Development Phase of Primary Product:
Phase I
Number Of Unlicensed Products (For Which You Are Seeking Partners):
8
Speaker
